👪

Inheritance

1

Mitochondrial inheritance HP:0001427

MELAS is maternally inherited through the mitochondrial genome. Clinical expression depends on the heteroplasmy level of mutant mtDNA, with a threshold effect.

Mitochondrial inheritance

Show evidence (2 references)

PMID:26095523 SUPPORT Human Clinical

"Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is one of the most frequent maternally inherited mitochondrial disorders."

Establishes MELAS as a maternally inherited mitochondrial disorder.

PMID:2102678 SUPPORT Human Clinical

"Southern blot analysis confirmed that the mutant DNA always coexists with the wild-type DNA"

Documents heteroplasmy (coexistence of mutant and wild-type mtDNA), the basis for the threshold effect in MELAS.

◆

Subtypes

3

MT-TL1 m.3243A>G (classic MELAS)

The most common form, caused by the m.3243A>G transition in MT-TL1 (mitochondrial tRNA-Leu(UUR)), accounting for roughly 80% of MELAS cases.

Other MT-TL1 (tRNA-Leu(UUR)) variants

A minority of MELAS cases caused by non-3243 pathogenic variants in MT-TL1, most notably m.3271T>C, which also impair tRNA-Leu(UUR) function.

MT-ND5 and other mitochondrial-gene MELAS

MELAS-spectrum disease caused by variants outside MT-TL1, particularly in the complex I subunit gene MT-ND5, and occasionally other mitochondrial tRNA or protein-coding genes.

⚙

Pathophysiology

5

Mitochondrial tRNA-Leu(UUR) translation defect

The m.3243A>G variant in MT-TL1 disrupts the structure and aminoacylation of mitochondrial tRNA-Leu(UUR), impairing mitochondrial protein synthesis (translation) of the mtDNA-encoded respiratory chain subunits.

MT-TL1 hgnc:7490

tRNA aminoacylation for protein translation GO:0006418 ↓ DECREASED mitochondrial translation GO:0032543 ↓ DECREASED

Downstream

Oxidative phosphorylation deficiency Defective synthesis of mtDNA-encoded subunits reduces assembly and activity of the respiratory chain complexes, especially complex I.

Show evidence (2 references)

PMID:2102678 SUPPORT Human Clinical

"Here we report an A-to-G transition mutation at nucleotide pair 3,243 in the dihydrouridine loop of mitochondrial tRNA(Leu)(UUR) that is specific to patients with MELAS."

The foundational paper identifying the m.3243A>G transition in mitochondrial tRNA-Leu(UUR) (MT-TL1) as the MELAS-specific lesion.

PMID:23392880 SUPPORT In Vitro

"These mutations reduce both the aminoacylation of tRNA(Leu(UUR)) and a posttranslational modification in the wobble position of tRNA(Leu(UUR)). Both changes result in reduced transcription of mitochondria-encoded proteins"

Directly supports the mechanism that MT-TL1 mutations impair tRNA aminoacylation and wobble modification, reducing mitochondrial protein synthesis.

Oxidative phosphorylation deficiency

Impaired mitochondrial translation reduces the abundance and activity of respiratory chain complexes, lowering ATP synthesis through oxidative phosphorylation. The defect becomes clinically apparent above a heteroplasmy threshold of mutant mtDNA.

oxidative phosphorylation GO:0006119 ↓ DECREASED aerobic respiration GO:0009060 ↓ DECREASED

Downstream

Cellular energy failure and lactic acidosis Reduced ATP synthesis forces a shift to anaerobic glycolysis, raising lactate, and starves high-energy-demand tissues (brain, muscle, vascular endothelium and smooth muscle).

Show evidence (1 reference)

PMID:26851065 SUPPORT Human Clinical

"The pathogenesis of this syndrome is not fully understood and believed to result from several interacting mechanisms including impaired mitochondrial energy production, microvasculature angiopathy, and nitric oxide (NO) deficiency."

Establishes impaired mitochondrial energy production (OXPHOS deficiency) as a core pathogenic mechanism of MELAS.

Cellular energy failure and lactic acidosis

OXPHOS deficiency drives a compensatory increase in anaerobic glycolysis, producing elevated blood and CSF lactate. Energy failure preferentially affects metabolically demanding tissues, underlying encephalopathy, myopathy, and endocrine dysfunction.

neuron CL:0000540 skeletal muscle fiber CL:0008002

generation of precursor metabolites and energy GO:0006091 ↓ DECREASED

Downstream

Mitochondrial angiopathy and NO deficiency Energy failure in cerebral small-vessel endothelium and smooth muscle drives mitochondrial angiopathy and impaired nitric oxide availability.

Show evidence (1 reference)

PMID:26095523 SUPPORT Human Clinical

"The inability of dysfunctional mitochondria to generate sufficient energy to meet the needs of various organs results in the multi-organ dysfunction observed in MELAS syndrome."

Supports cellular energy failure in high-demand tissues as the link between OXPHOS deficiency and the multisystem phenotype.

Mitochondrial angiopathy and NO deficiency

Mitochondrial proliferation in the smooth muscle and endothelial cells of cerebral small vessels (mitochondrial angiopathy) and impaired nitric oxide availability produce endothelial dysfunction and impaired microvascular perfusion. This NO-deficient endothelial dysfunction is the target of L-arginine therapy.

smooth muscle cell CL:0000192 endothelial cell CL:0000115

nitric oxide biosynthetic process GO:0006809 ↓ DECREASED

Downstream

Stroke-like episodes Mitochondrial angiopathy and NO deficiency, together with neuronal energy failure, converge to produce stroke-like episodes that do not respect classic vascular territories.

Show evidence (2 references)

PMID:26095523 SUPPORT Human Clinical

"Energy deficiency can also stimulate mitochondrial proliferation in the smooth muscle and endothelial cells of small blood vessels leading to angiopathy and impaired blood perfusion in the microvasculature of several organs."

Directly supports the mitochondrial angiopathy mechanism in cerebral small vessels underlying stroke-like episodes.

PMID:31693521 SUPPORT Human Clinical

"MELAS is associated with endothelial dysfunction by decreased plasma L-arginine, nitric oxide (NO), and cyclic guanosine monophosphate."

Supports impaired nitric oxide availability and endothelial dysfunction as a contributor to stroke-like episodes.

Stroke-like episodes

Acute neurological deficits with neuroimaging lesions that do not conform to classic vascular territories, the defining clinical manifestation of MELAS, arising from mitochondrial angiopathy, NO deficiency, and neuronal energy failure.

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"During the stroke-like episodes neuroimaging shows increased T2-weighted signal areas that do not correspond to the classic vascular distribution (hence the term "stroke-like")."

GeneReviews documents stroke-like episodes with non-vascular-territory neuroimaging lesions as the defining MELAS feature, the clinical outcome of the angiopathy and energy-failure mechanisms.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

16

Cardiovascular 1

Cardiomyopathy Cardiomyopathy HP:0001638

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"Ptosis, cardiomyopathy, cardiac conduction defects, nephropathy, and migraine headache are treated in the standard manner."

GeneReviews documents cardiomyopathy and cardiac conduction defects as manifestations of MELAS requiring standard management.

Digestive 1

Recurrent vomiting Vomiting HP:0002013

Temporal: RECURRENT

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"muscle weakness and exercise intolerance, normal early psychomotor development, recurrent headaches, recurrent vomiting, hearing impairment, peripheral neuropathy, learning disability, and short stature"

GeneReviews lists recurrent vomiting among the common manifestations of MELAS.

Ear 1

Sensorineural hearing loss Sensorineural hearing impairment HP:0000407

Show evidence (1 reference)

PMID:26095523 SUPPORT Human Clinical

"MELAS syndrome is a multi-organ disease with broad manifestations including stroke-like episodes, dementia, epilepsy, lactic acidemia, myopathy, recurrent headaches, hearing impairment, diabetes, and short stature."

The El-Hattab review lists hearing impairment among the broad manifestations of MELAS.

Endocrine 1

Diabetes mellitus Diabetes mellitus HP:0000819

Show evidence (1 reference)

PMID:26095523 SUPPORT Human Clinical

"MELAS syndrome is a multi-organ disease with broad manifestations including stroke-like episodes, dementia, epilepsy, lactic acidemia, myopathy, recurrent headaches, hearing impairment, diabetes, and short stature."

The El-Hattab review lists diabetes among the broad manifestations of MELAS, reflecting the endocrine involvement of the m.3243A>G mutation.

Metabolism 1

Lactic acidosis Lactic acidosis HP:0003128

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"Lactic acidemia is very common and muscle biopsies typically show ragged red fibers."

GeneReviews documents lactic acidemia as a very common feature of MELAS.

Musculoskeletal 1

Mitochondrial myopathy Myopathy HP:0003198

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"Common clinical manifestations include stroke-like episodes, encephalopathy with seizures and/or dementia, muscle weakness and exercise intolerance"

GeneReviews lists muscle weakness and exercise intolerance, the clinical expression of mitochondrial myopathy, among common manifestations.

Nervous System 4

Seizures Seizure HP:0001250

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"Common clinical manifestations include stroke-like episodes, encephalopathy with seizures and/or dementia, muscle weakness and exercise intolerance"

GeneReviews lists encephalopathy with seizures among the common manifestations of MELAS.

Encephalopathy Encephalopathy HP:0001298

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"Common clinical manifestations include stroke-like episodes, encephalopathy with seizures and/or dementia, muscle weakness and exercise intolerance"

GeneReviews lists encephalopathy with seizures and/or dementia among the common manifestations of MELAS.

Migraine-like headaches Migraine HP:0002076

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"muscle weakness and exercise intolerance, normal early psychomotor development, recurrent headaches, recurrent vomiting, hearing impairment, peripheral neuropathy, learning disability, and short stature"

GeneReviews lists recurrent headaches among the common manifestations; these are typically migraine-like and often herald stroke-like episodes.

Peripheral neuropathy Peripheral neuropathy HP:0009830

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"muscle weakness and exercise intolerance, normal early psychomotor development, recurrent headaches, recurrent vomiting, hearing impairment, peripheral neuropathy, learning disability, and short stature"

GeneReviews lists peripheral neuropathy among the common manifestations of MELAS.

Constitutional 1

Exercise intolerance Exercise intolerance HP:0003546

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"Common clinical manifestations include stroke-like episodes, encephalopathy with seizures and/or dementia, muscle weakness and exercise intolerance"

GeneReviews lists exercise intolerance among the common manifestations of MELAS.

Growth 1

Short stature Short stature HP:0004322

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"muscle weakness and exercise intolerance, normal early psychomotor development, recurrent headaches, recurrent vomiting, hearing impairment, peripheral neuropathy, learning disability, and short stature"

GeneReviews lists short stature among the common manifestations of MELAS.

Other 4

Stroke-like episodes Stroke-like episode HP:0002401

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"During the stroke-like episodes neuroimaging shows increased T2-weighted signal areas that do not correspond to the classic vascular distribution (hence the term "stroke-like")."

GeneReviews documents stroke-like episodes with non-vascular-territory neuroimaging lesions as the defining MELAS feature.

Ragged-red fibers Ragged-red muscle fibers HP:0003200

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"Lactic acidemia is very common and muscle biopsies typically show ragged red fibers."

GeneReviews documents ragged-red fibers as a typical muscle biopsy finding in MELAS.

Learning disability Specific learning disability HP:0001328

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"muscle weakness and exercise intolerance, normal early psychomotor development, recurrent headaches, recurrent vomiting, hearing impairment, peripheral neuropathy, learning disability, and short stature"

GeneReviews lists learning disability among the common manifestations of MELAS.

Cortical visual impairment Hemianopia HP:0012377

Show evidence (1 reference)

PMID:31693521 SUPPORT Human Clinical

"the sudden, transient, and recurrent development of stroke-resembling symptoms (headache, nausea/vomiting, visual disturbance/visual field abnormalities, seizures, and impaired consciousness: ictus)"

Visual field abnormalities (e.g., hemianopia) commonly accompany occipital stroke-like episodes in MELAS.

🧬

Genetic Associations

2

MT-TL1 m.3243A>G (The m.3243A>G point mutation in MT-TL1 (mitochondrial tRNA-Leu(UUR)) is the most common cause of MELAS, found in roughly 80% of patients. Disease expression depends on the heteroplasmy level of mutant mtDNA.)

Gene: MT-TL1 hgnc:7490

Mitochondrial inheritance

Show evidence (2 references)

PMID:20301411 SUPPORT Human Clinical

"The m.3243A>G pathogenic variant in the mitochondrial gene MT-TL1 is present in approximately 80% of individuals with MELAS."

GeneReviews establishes m.3243A>G in MT-TL1 as the most common cause of MELAS (~80% of cases).

PMID:2102678 SUPPORT Human Clinical

"The mutation was present in 26 out of 31 independent MELAS patients and 1 out of 29 CPEO patients, but absent in the 5 MERRF and 50 controls tested."

Original genotyping data establishing the m.3243A>G variant as MELAS-specific.

MT-ND5 and other mitochondrial-gene variants (A minority of MELAS cases are caused by variants outside MT-TL1, including the complex I subunit gene MT-ND5.)

Gene: MT-ND5 hgnc:7461

Show evidence (1 reference)

PMID:20301411 SUPPORT Human Clinical

"Pathogenic variants in MT-TL1 or other mtDNA genes, particularly MT-ND5, can also cause this disorder."

GeneReviews documents MT-ND5 and other mtDNA genes as additional causes of MELAS beyond the common MT-TL1 m.3243A>G variant.

💊

Medical Actions

4

L-arginine therapy

Action: Pharmacotherapy NCIT:C15986

Agent: L-arginine CHEBI:16467

Intravenous L-arginine in the acute phase and oral supplementation for prophylaxis aims to restore nitric oxide availability and improve endothelial function, reducing the frequency and severity of stroke-like episodes.

Mechanism Target:

RESTORES Mitochondrial angiopathy and NO deficiency — L-arginine, a nitric oxide precursor, aims to restore nitric oxide availability and improve endothelial function at the angiopathy node, reducing the frequency and severity of stroke-like episodes.

Show evidence (2 references)

PMID:26095523 SUPPORT Human Clinical

"Unblinded studies showed that l-arginine therapy improves stroke-like episode symptoms and decreases the frequency and severity of these episodes."

Supports L-arginine as a therapy that reduces stroke-like episode frequency and severity in MELAS.

PMID:31693521 SUPPORT Human Clinical

"the systematic administration of L-arginine to patients with MELAS significantly improved the survival curve of patients compared with natural history."

Clinical trial follow-up data supporting survival benefit of systematic L-arginine therapy in MELAS.

Taurine supplementation

Action: dietary intervention MAXO:0000088

Agent: taurine CHEBI:15891

Oral taurine supplementation aims to restore taurine modification of the wobble uridine of mutant mitochondrial tRNA-Leu(UUR), improving codon decoding and reducing stroke-like episode recurrence.

Show evidence (2 references)

PMID:29666206 SUPPORT Human Clinical

"Taurine reduced the annual relapse rate of stroke-like episodes from 2.22 to 0.72 (P=0.001)."

A multicentre phase III trial showing high-dose taurine significantly reduced stroke-like episode recurrence in MELAS.

PMID:29666206 SUPPORT Human Clinical

"a taurine modification defect at the first anticodon nucleotide of mitochondrial tRNALeu(UUR), resulting in failure to decode codons accurately"

Provides the molecular rationale: taurine restores wobble-uridine modification of mutant tRNA-Leu(UUR), improving codon decoding.

Citrulline supplementation

Action: Pharmacotherapy NCIT:C15986

Agent: L-citrulline CHEBI:16349

Oral citrulline, a nitric oxide precursor, increases arginine availability and nitric oxide production. Stable-isotope studies suggest citrulline may be a more effective NO precursor than arginine in MELAS.

Mechanism Target:

RESTORES Mitochondrial angiopathy and NO deficiency — Citrulline increases intracellular arginine availability and nitric oxide synthesis, targeting the NO-deficient endothelial dysfunction at the angiopathy node.

Show evidence (1 reference)

PMID:26851065 SUPPORT Human Clinical

"The greater effect of citrulline in increasing NO production is due to its greater ability to increase arginine availability particularly in the intracellular compartment in which NO synthesis takes place."

Stable-isotope study showing citrulline increases NO production more effectively than arginine in children with MELAS, supporting it as a NO precursor therapy.

Supportive mitochondrial disease management

Action: supportive care MAXO:0000950

Supportive care including antiseizure medications, management of diabetes and hearing loss, avoidance of mitochondrial toxins, and mitochondrial cofactor supplementation (e.g., coenzyme Q10, L-carnitine).

Show evidence (2 references)

PMID:26095523 SUPPORT Human Clinical

"Management is largely symptomatic and should involve a multidisciplinary team."

Supports symptomatic, multidisciplinary supportive management as the mainstay of MELAS care.

PMID:26095523 PARTIAL Human Clinical

"Additionally, carnitine and coenzyme Q10 are commonly used in MELAS syndrome without proven efficacy."

Supports common use of carnitine and coenzyme Q10 cofactors, while noting their efficacy is unproven (hence PARTIAL).

🌍

Environmental Factors

1

Mitochondrial toxins and agents to avoid

Certain drugs and exposures can precipitate or worsen MELAS by impairing mitochondrial function or triggering lactic acidosis, and should be avoided.

Show evidence (1 reference)

PMID:20301411 SUPPORT Other

"Mitochondrial toxins, including aminoglycoside antibiotics, linezolid, cigarettes, and alcohol; valproic acid for seizure treatment; metformin because of its propensity to cause lactic acidosis; dichloroacetate (DCA) because of increased risk for peripheral neuropathy."

GeneReviews lists agents and circumstances to avoid in MELAS, including aminoglycosides, linezolid, valproic acid, metformin, dichloroacetate, cigarettes, and alcohol.

{ }

Source YAML

click to show

name: MELAS Syndrome
creation_date: "2026-06-08T00:00:00Z"
description: >-
  MELAS syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and
  Stroke-like episodes) is a maternally inherited multisystem mitochondrial
  disease caused most often by the m.3243A>G point mutation in the MT-TL1 gene,
  which encodes the mitochondrial tRNA-Leu(UUR). The mutation impairs
  mitochondrial tRNA aminoacylation and translation, producing a respiratory
  chain (oxidative phosphorylation) deficiency that manifests above a
  heteroplasmy threshold. Energy failure in brain, muscle, and small blood
  vessels drives the cardinal stroke-like episodes (often in non-vascular
  territories), lactic acidosis, seizures, myopathy, sensorineural hearing
  loss, and diabetes mellitus. Other MT-TL1 variants and variants in additional
  mitochondrial genes (notably MT-ND5) cause a minority of cases.
references:
- reference: PMID:20301411
  title: MELAS.
  tags:
  - GeneReviews
category: Mendelian
parents:
- hereditary disease
- mitochondrial disease
disease_term:
  preferred_term: MELAS syndrome
  term:
    id: MONDO:0010789
    label: MELAS syndrome
has_subtypes:
- name: MT-TL1 m.3243A>G
  display_name: MT-TL1 m.3243A>G (classic MELAS)
  description: >-
    The most common form, caused by the m.3243A>G transition in MT-TL1
    (mitochondrial tRNA-Leu(UUR)), accounting for roughly 80% of MELAS cases.
- name: Other MT-TL1 variants
  display_name: Other MT-TL1 (tRNA-Leu(UUR)) variants
  description: >-
    A minority of MELAS cases caused by non-3243 pathogenic variants in MT-TL1,
    most notably m.3271T>C, which also impair tRNA-Leu(UUR) function.
- name: MT-ND5 and other genes
  display_name: MT-ND5 and other mitochondrial-gene MELAS
  description: >-
    MELAS-spectrum disease caused by variants outside MT-TL1, particularly in
    the complex I subunit gene MT-ND5, and occasionally other mitochondrial
    tRNA or protein-coding genes.
prevalence:
- population: Adults in Southwest Finland (2022, m.3243A>G-related disease)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 4.2
  percentage: 4.2/100,000
  evidence:
  - reference: PMID:38361968
    reference_title: "Incidence and prevalence of mtDNA-related adult mitochondrial disease in Southwest Finland, 2009-2022: an observational, population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The prevalence of adult mtDNA disease associated with m.3243A>G was
      4.2/100 000 (95% CI, 2.5 to 6.7)
    explanation: >-
      Population-based prevalence of adult m.3243A>G-related mitochondrial
      disease, the genotype underlying most MELAS.
  notes: >-
    m.3243A>G underlies multiple overlapping clinical syndromes (MELAS, MIDD),
    so this figure reflects the broader m.3243A>G disease population rather than
    classic MELAS specifically.
pathophysiology:
- name: Mitochondrial tRNA-Leu(UUR) translation defect
  description: >-
    The m.3243A>G variant in MT-TL1 disrupts the structure and aminoacylation
    of mitochondrial tRNA-Leu(UUR), impairing mitochondrial protein synthesis
    (translation) of the mtDNA-encoded respiratory chain subunits.
  genes:
  - preferred_term: MT-TL1
    term:
      id: hgnc:7490
      label: MT-TL1
  biological_processes:
  - preferred_term: tRNA aminoacylation for protein translation
    modifier: DECREASED
    term:
      id: GO:0006418
      label: tRNA aminoacylation for protein translation
  - preferred_term: mitochondrial translation
    modifier: DECREASED
    term:
      id: GO:0032543
      label: mitochondrial translation
  evidence:
  - reference: PMID:2102678
    reference_title: A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we report an A-to-G transition mutation at nucleotide pair 3,243 in
      the dihydrouridine loop of mitochondrial tRNA(Leu)(UUR) that is specific
      to patients with MELAS.
    explanation: >-
      The foundational paper identifying the m.3243A>G transition in
      mitochondrial tRNA-Leu(UUR) (MT-TL1) as the MELAS-specific lesion.
  - reference: PMID:23392880
    reference_title: Taurine deficiency and MELAS are closely related syndromes.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These mutations reduce both the aminoacylation of tRNA(Leu(UUR)) and a
      posttranslational modification in the wobble position of tRNA(Leu(UUR)).
      Both changes result in reduced transcription of mitochondria-encoded
      proteins
    explanation: >-
      Directly supports the mechanism that MT-TL1 mutations impair tRNA
      aminoacylation and wobble modification, reducing mitochondrial protein
      synthesis.
  downstream:
  - target: Oxidative phosphorylation deficiency
    causal_link_type: DIRECT
    description: >-
      Defective synthesis of mtDNA-encoded subunits reduces assembly and
      activity of the respiratory chain complexes, especially complex I.
- name: Oxidative phosphorylation deficiency
  conforms_to: "mitochondrial_dysfunction#Bioenergetic Decline and Oxidative Stress"
  description: >-
    Impaired mitochondrial translation reduces the abundance and activity of
    respiratory chain complexes, lowering ATP synthesis through oxidative
    phosphorylation. The defect becomes clinically apparent above a heteroplasmy
    threshold of mutant mtDNA.
  biological_processes:
  - preferred_term: oxidative phosphorylation
    modifier: DECREASED
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  - preferred_term: aerobic respiration
    modifier: DECREASED
    term:
      id: GO:0009060
      label: aerobic respiration
  evidence:
  - reference: PMID:26851065
    reference_title: Impaired nitric oxide production in children with MELAS syndrome and the effect of arginine and citrulline supplementation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pathogenesis of this syndrome is not fully understood and believed to
      result from several interacting mechanisms including impaired
      mitochondrial energy production, microvasculature angiopathy, and nitric
      oxide (NO) deficiency.
    explanation: >-
      Establishes impaired mitochondrial energy production (OXPHOS deficiency)
      as a core pathogenic mechanism of MELAS.
  downstream:
  - target: Cellular energy failure and lactic acidosis
    causal_link_type: DIRECT
    description: >-
      Reduced ATP synthesis forces a shift to anaerobic glycolysis, raising
      lactate, and starves high-energy-demand tissues (brain, muscle, vascular
      endothelium and smooth muscle).
- name: Cellular energy failure and lactic acidosis
  description: >-
    OXPHOS deficiency drives a compensatory increase in anaerobic glycolysis,
    producing elevated blood and CSF lactate. Energy failure preferentially
    affects metabolically demanding tissues, underlying encephalopathy,
    myopathy, and endocrine dysfunction.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  biological_processes:
  - preferred_term: generation of precursor metabolites and energy
    modifier: DECREASED
    term:
      id: GO:0006091
      label: generation of precursor metabolites and energy
  evidence:
  - reference: PMID:26095523
    reference_title: "MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The inability of dysfunctional mitochondria to generate sufficient energy
      to meet the needs of various organs results in the multi-organ
      dysfunction observed in MELAS syndrome.
    explanation: >-
      Supports cellular energy failure in high-demand tissues as the link
      between OXPHOS deficiency and the multisystem phenotype.
  downstream:
  - target: Mitochondrial angiopathy and NO deficiency
    causal_link_type: DIRECT
    description: >-
      Energy failure in cerebral small-vessel endothelium and smooth muscle
      drives mitochondrial angiopathy and impaired nitric oxide availability.
- name: Mitochondrial angiopathy and NO deficiency
  description: >-
    Mitochondrial proliferation in the smooth muscle and endothelial cells of
    cerebral small vessels (mitochondrial angiopathy) and impaired nitric oxide
    availability produce endothelial dysfunction and impaired microvascular
    perfusion. This NO-deficient endothelial dysfunction is the target of
    L-arginine therapy.
  cell_types:
  - preferred_term: smooth muscle cell
    term:
      id: CL:0000192
      label: smooth muscle cell
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: nitric oxide biosynthetic process
    modifier: DECREASED
    term:
      id: GO:0006809
      label: nitric oxide biosynthetic process
  evidence:
  - reference: PMID:26095523
    reference_title: "MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Energy deficiency can also stimulate mitochondrial proliferation in the
      smooth muscle and endothelial cells of small blood vessels leading to
      angiopathy and impaired blood perfusion in the microvasculature of
      several organs.
    explanation: >-
      Directly supports the mitochondrial angiopathy mechanism in cerebral
      small vessels underlying stroke-like episodes.
  - reference: PMID:31693521
    reference_title: Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MELAS is associated with endothelial dysfunction by decreased plasma
      L-arginine, nitric oxide (NO), and cyclic guanosine monophosphate.
    explanation: >-
      Supports impaired nitric oxide availability and endothelial dysfunction
      as a contributor to stroke-like episodes.
  downstream:
  - target: Stroke-like episodes
    causal_link_type: DIRECT
    description: >-
      Mitochondrial angiopathy and NO deficiency, together with neuronal energy
      failure, converge to produce stroke-like episodes that do not respect
      classic vascular territories.
- name: Stroke-like episodes
  description: >-
    Acute neurological deficits with neuroimaging lesions that do not conform to
    classic vascular territories, the defining clinical manifestation of MELAS,
    arising from mitochondrial angiopathy, NO deficiency, and neuronal energy
    failure.
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      During the stroke-like episodes neuroimaging shows increased T2-weighted
      signal areas that do not correspond to the classic vascular distribution
      (hence the term "stroke-like").
    explanation: >-
      GeneReviews documents stroke-like episodes with non-vascular-territory
      neuroimaging lesions as the defining MELAS feature, the clinical outcome
      of the angiopathy and energy-failure mechanisms.
phenotypes:
- name: Stroke-like episodes
  description: >-
    Acute neurological deficits with neuroimaging lesions that do not conform to
    classic vascular territories, a defining feature of MELAS.
  phenotype_term:
    preferred_term: Stroke-like episode
    term:
      id: HP:0002401
      label: Stroke-like episode
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      During the stroke-like episodes neuroimaging shows increased T2-weighted
      signal areas that do not correspond to the classic vascular distribution
      (hence the term "stroke-like").
    explanation: >-
      GeneReviews documents stroke-like episodes with non-vascular-territory
      neuroimaging lesions as the defining MELAS feature.
- name: Lactic acidosis
  description: >-
    Elevated lactate in blood and cerebrospinal fluid from the shift toward
    anaerobic glycolysis.
  phenotype_term:
    preferred_term: Lactic acidosis
    term:
      id: HP:0003128
      label: Lactic acidosis
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lactic acidemia is very common and muscle biopsies typically show ragged
      red fibers.
    explanation: >-
      GeneReviews documents lactic acidemia as a very common feature of MELAS.
- name: Seizures
  description: Epileptic seizures, often focal or generalized, frequently accompanying stroke-like episodes.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common clinical manifestations include stroke-like episodes,
      encephalopathy with seizures and/or dementia, muscle weakness and
      exercise intolerance
    explanation: >-
      GeneReviews lists encephalopathy with seizures among the common
      manifestations of MELAS.
- name: Encephalopathy
  description: Encephalopathy with cognitive decline, sometimes progressing to dementia.
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common clinical manifestations include stroke-like episodes,
      encephalopathy with seizures and/or dementia, muscle weakness and
      exercise intolerance
    explanation: >-
      GeneReviews lists encephalopathy with seizures and/or dementia among the
      common manifestations of MELAS.
- name: Mitochondrial myopathy
  description: Proximal muscle weakness, exercise intolerance, and ragged-red fibers on muscle biopsy.
  phenotype_term:
    preferred_term: Myopathy
    term:
      id: HP:0003198
      label: Myopathy
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common clinical manifestations include stroke-like episodes,
      encephalopathy with seizures and/or dementia, muscle weakness and
      exercise intolerance
    explanation: >-
      GeneReviews lists muscle weakness and exercise intolerance, the clinical
      expression of mitochondrial myopathy, among common manifestations.
- name: Ragged-red fibers
  description: Ragged-red fibers on modified Gomori trichrome staining of muscle biopsy, reflecting mitochondrial proliferation.
  phenotype_term:
    preferred_term: Ragged-red muscle fibers
    term:
      id: HP:0003200
      label: Ragged-red muscle fibers
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lactic acidemia is very common and muscle biopsies typically show ragged
      red fibers.
    explanation: >-
      GeneReviews documents ragged-red fibers as a typical muscle biopsy
      finding in MELAS.
- name: Exercise intolerance
  description: Reduced exercise capacity due to impaired mitochondrial energy production.
  phenotype_term:
    preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common clinical manifestations include stroke-like episodes,
      encephalopathy with seizures and/or dementia, muscle weakness and
      exercise intolerance
    explanation: >-
      GeneReviews lists exercise intolerance among the common manifestations of
      MELAS.
- name: Sensorineural hearing loss
  description: Progressive sensorineural hearing impairment, common in m.3243A>G carriers.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:26095523
    reference_title: "MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MELAS syndrome is a multi-organ disease with broad manifestations
      including stroke-like episodes, dementia, epilepsy, lactic acidemia,
      myopathy, recurrent headaches, hearing impairment, diabetes, and short
      stature.
    explanation: >-
      The El-Hattab review lists hearing impairment among the broad
      manifestations of MELAS.
- name: Diabetes mellitus
  description: Diabetes mellitus, part of the maternally inherited diabetes and deafness (MIDD) overlap of the m.3243A>G mutation.
  phenotype_term:
    preferred_term: Diabetes mellitus
    term:
      id: HP:0000819
      label: Diabetes mellitus
  evidence:
  - reference: PMID:26095523
    reference_title: "MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MELAS syndrome is a multi-organ disease with broad manifestations
      including stroke-like episodes, dementia, epilepsy, lactic acidemia,
      myopathy, recurrent headaches, hearing impairment, diabetes, and short
      stature.
    explanation: >-
      The El-Hattab review lists diabetes among the broad manifestations of
      MELAS, reflecting the endocrine involvement of the m.3243A>G mutation.
- name: Migraine-like headaches
  description: Recurrent migraine-like headaches, often heralding stroke-like episodes.
  phenotype_term:
    preferred_term: Migraine
    term:
      id: HP:0002076
      label: Migraine
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      muscle weakness and exercise intolerance, normal early psychomotor
      development, recurrent headaches, recurrent vomiting, hearing impairment,
      peripheral neuropathy, learning disability, and short stature
    explanation: >-
      GeneReviews lists recurrent headaches among the common manifestations;
      these are typically migraine-like and often herald stroke-like episodes.
- name: Short stature
  description: Short stature is common in individuals with MELAS.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      muscle weakness and exercise intolerance, normal early psychomotor
      development, recurrent headaches, recurrent vomiting, hearing impairment,
      peripheral neuropathy, learning disability, and short stature
    explanation: >-
      GeneReviews lists short stature among the common manifestations of MELAS.
- name: Recurrent vomiting
  description: Recurrent vomiting is a common manifestation of MELAS, often accompanying stroke-like episodes.
  phenotype_term:
    preferred_term: Recurrent vomiting
    term:
      id: HP:0002013
      label: Vomiting
    temporality: RECURRENT
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      muscle weakness and exercise intolerance, normal early psychomotor
      development, recurrent headaches, recurrent vomiting, hearing impairment,
      peripheral neuropathy, learning disability, and short stature
    explanation: >-
      GeneReviews lists recurrent vomiting among the common manifestations of
      MELAS.
- name: Peripheral neuropathy
  description: Peripheral neuropathy is a common manifestation of MELAS.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      muscle weakness and exercise intolerance, normal early psychomotor
      development, recurrent headaches, recurrent vomiting, hearing impairment,
      peripheral neuropathy, learning disability, and short stature
    explanation: >-
      GeneReviews lists peripheral neuropathy among the common manifestations of
      MELAS.
- name: Learning disability
  description: Learning disability is a common manifestation of MELAS.
  phenotype_term:
    preferred_term: Learning disability
    term:
      id: HP:0001328
      label: Specific learning disability
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      muscle weakness and exercise intolerance, normal early psychomotor
      development, recurrent headaches, recurrent vomiting, hearing impairment,
      peripheral neuropathy, learning disability, and short stature
    explanation: >-
      GeneReviews lists learning disability among the common manifestations of
      MELAS.
- name: Cardiomyopathy
  description: >-
    Cardiomyopathy and cardiac conduction defects occur in MELAS, reflecting
    energy failure in cardiac tissue.
  phenotype_term:
    preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Ptosis, cardiomyopathy, cardiac conduction defects, nephropathy, and
      migraine headache are treated in the standard manner.
    explanation: >-
      GeneReviews documents cardiomyopathy and cardiac conduction defects as
      manifestations of MELAS requiring standard management.
- name: Cortical visual impairment
  description: Visual impairment, including hemianopia or cortical blindness following occipital stroke-like episodes.
  phenotype_term:
    preferred_term: Hemianopia
    term:
      id: HP:0012377
      label: Hemianopia
  evidence:
  - reference: PMID:31693521
    reference_title: Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the sudden, transient, and recurrent development of stroke-resembling
      symptoms (headache, nausea/vomiting, visual disturbance/visual field
      abnormalities, seizures, and impaired consciousness: ictus)
    explanation: >-
      Visual field abnormalities (e.g., hemianopia) commonly accompany
      occipital stroke-like episodes in MELAS.
genetic:
- name: MT-TL1 m.3243A>G
  gene_term:
    preferred_term: MT-TL1
    term:
      id: hgnc:7490
      label: MT-TL1
  association: >-
    The m.3243A>G point mutation in MT-TL1 (mitochondrial tRNA-Leu(UUR)) is the
    most common cause of MELAS, found in roughly 80% of patients. Disease
    expression depends on the heteroplasmy level of mutant mtDNA.
  subtype: MT-TL1 m.3243A>G
  inheritance:
  - name: Mitochondrial inheritance
    inheritance_term:
      preferred_term: Mitochondrial inheritance
      term:
        id: HP:0001427
        label: Mitochondrial inheritance
    evidence:
    - reference: PMID:24846800
      reference_title: "Detection rates and phenotypic spectrum of m.3243A>G in the MT-TL1 gene: a molecular diagnostic laboratory perspective."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        factors including random mitochondrial segregation and consequent
        variable tissue heteroplasmy are recognised to contribute to a much
        broader phenotypic spectrum associated with the MT-TL1 m.3243A>G
        mutation
      explanation: >-
        Supports maternal mitochondrial inheritance with heteroplasmy-dependent,
        variable phenotypic expression of the m.3243A>G mutation.
    - reference: PMID:37988592
      reference_title: Penetrance and expressivity of mitochondrial variants in a large clinically unselected population.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Multi-system disease risk and penetrance of diabetes, deafness and
        heart failure greatly increased with m.3243A>G level ≥ 10%.
      explanation: >-
        UK Biobank data quantifying the heteroplasmy threshold effect: penetrance
        of multisystem disease rises sharply once m.3243A>G heteroplasmy reaches
        ≥10%.
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The m.3243A>G pathogenic variant in the mitochondrial gene MT-TL1 is
      present in approximately 80% of individuals with MELAS.
    explanation: >-
      GeneReviews establishes m.3243A>G in MT-TL1 as the most common cause of
      MELAS (~80% of cases).
  - reference: PMID:2102678
    reference_title: A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mutation was present in 26 out of 31 independent MELAS patients and 1
      out of 29 CPEO patients, but absent in the 5 MERRF and 50 controls tested.
    explanation: >-
      Original genotyping data establishing the m.3243A>G variant as
      MELAS-specific.
- name: MT-ND5 and other mitochondrial-gene variants
  gene_term:
    preferred_term: MT-ND5
    term:
      id: hgnc:7461
      label: MT-ND5
  association: >-
    A minority of MELAS cases are caused by variants outside MT-TL1, including
    the complex I subunit gene MT-ND5.
  subtype: MT-ND5 and other genes
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pathogenic variants in MT-TL1 or other mtDNA genes, particularly MT-ND5,
      can also cause this disorder.
    explanation: >-
      GeneReviews documents MT-ND5 and other mtDNA genes as additional causes of
      MELAS beyond the common MT-TL1 m.3243A>G variant.
treatments:
- name: L-arginine therapy
  description: >-
    Intravenous L-arginine in the acute phase and oral supplementation for
    prophylaxis aims to restore nitric oxide availability and improve
    endothelial function, reducing the frequency and severity of stroke-like
    episodes.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: L-arginine
      term:
        id: CHEBI:16467
        label: L-arginine
  target_mechanisms:
  - target: Mitochondrial angiopathy and NO deficiency
    treatment_effect: RESTORES
    description: >-
      L-arginine, a nitric oxide precursor, aims to restore nitric oxide
      availability and improve endothelial function at the angiopathy node,
      reducing the frequency and severity of stroke-like episodes.
  evidence:
  - reference: PMID:26095523
    reference_title: "MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Unblinded studies showed that l-arginine therapy improves stroke-like
      episode symptoms and decreases the frequency and severity of these
      episodes.
    explanation: >-
      Supports L-arginine as a therapy that reduces stroke-like episode
      frequency and severity in MELAS.
  - reference: PMID:31693521
    reference_title: Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the systematic administration of L-arginine to patients with MELAS
      significantly improved the survival curve of patients compared with
      natural history.
    explanation: >-
      Clinical trial follow-up data supporting survival benefit of systematic
      L-arginine therapy in MELAS.
- name: Taurine supplementation
  description: >-
    Oral taurine supplementation aims to restore taurine modification of the
    wobble uridine of mutant mitochondrial tRNA-Leu(UUR), improving codon
    decoding and reducing stroke-like episode recurrence.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
    therapeutic_agent:
    - preferred_term: taurine
      term:
        id: CHEBI:15891
        label: taurine
  evidence:
  - reference: PMID:29666206
    reference_title: "Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Taurine reduced the annual relapse rate of stroke-like episodes from 2.22
      to 0.72 (P=0.001).
    explanation: >-
      A multicentre phase III trial showing high-dose taurine significantly
      reduced stroke-like episode recurrence in MELAS.
  - reference: PMID:29666206
    reference_title: "Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a taurine modification defect at the first anticodon nucleotide of
      mitochondrial tRNALeu(UUR), resulting in failure to decode codons
      accurately
    explanation: >-
      Provides the molecular rationale: taurine restores wobble-uridine
      modification of mutant tRNA-Leu(UUR), improving codon decoding.
- name: Citrulline supplementation
  description: >-
    Oral citrulline, a nitric oxide precursor, increases arginine availability
    and nitric oxide production. Stable-isotope studies suggest citrulline may be
    a more effective NO precursor than arginine in MELAS.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: L-citrulline
      term:
        id: CHEBI:16349
        label: L-citrulline
  target_mechanisms:
  - target: Mitochondrial angiopathy and NO deficiency
    treatment_effect: RESTORES
    description: >-
      Citrulline increases intracellular arginine availability and nitric oxide
      synthesis, targeting the NO-deficient endothelial dysfunction at the
      angiopathy node.
  evidence:
  - reference: PMID:26851065
    reference_title: Impaired nitric oxide production in children with MELAS syndrome and the effect of arginine and citrulline supplementation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The greater effect of citrulline in increasing NO production is due to its
      greater ability to increase arginine availability particularly in the
      intracellular compartment in which NO synthesis takes place.
    explanation: >-
      Stable-isotope study showing citrulline increases NO production more
      effectively than arginine in children with MELAS, supporting it as a NO
      precursor therapy.
- name: Supportive mitochondrial disease management
  description: >-
    Supportive care including antiseizure medications, management of diabetes
    and hearing loss, avoidance of mitochondrial toxins, and mitochondrial
    cofactor supplementation (e.g., coenzyme Q10, L-carnitine).
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:26095523
    reference_title: "MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Management is largely symptomatic and should involve a multidisciplinary
      team.
    explanation: >-
      Supports symptomatic, multidisciplinary supportive management as the
      mainstay of MELAS care.
  - reference: PMID:26095523
    reference_title: "MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, carnitine and coenzyme Q10 are commonly used in MELAS
      syndrome without proven efficacy.
    explanation: >-
      Supports common use of carnitine and coenzyme Q10 cofactors, while noting
      their efficacy is unproven (hence PARTIAL).
inheritance:
- name: Mitochondrial inheritance
  inheritance_term:
    preferred_term: Mitochondrial inheritance
    term:
      id: HP:0001427
      label: Mitochondrial inheritance
  description: >-
    MELAS is maternally inherited through the mitochondrial genome. Clinical
    expression depends on the heteroplasmy level of mutant mtDNA, with a
    threshold effect.
  evidence:
  - reference: PMID:26095523
    reference_title: "MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like
      episodes (MELAS) syndrome is one of the most frequent maternally inherited
      mitochondrial disorders.
    explanation: >-
      Establishes MELAS as a maternally inherited mitochondrial disorder.
  - reference: PMID:2102678
    reference_title: A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Southern blot analysis confirmed that the mutant DNA always coexists with
      the wild-type DNA
    explanation: >-
      Documents heteroplasmy (coexistence of mutant and wild-type mtDNA), the
      basis for the threshold effect in MELAS.
environmental:
- name: Mitochondrial toxins and agents to avoid
  notes: >-
    Certain drugs and exposures can precipitate or worsen MELAS by impairing
    mitochondrial function or triggering lactic acidosis, and should be avoided.
  evidence:
  - reference: PMID:20301411
    reference_title: MELAS.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mitochondrial toxins, including aminoglycoside antibiotics, linezolid,
      cigarettes, and alcohol; valproic acid for seizure treatment; metformin
      because of its propensity to cause lactic acidosis; dichloroacetate (DCA)
      because of increased risk for peripheral neuropathy.
    explanation: >-
      GeneReviews lists agents and circumstances to avoid in MELAS, including
      aminoglycosides, linezolid, valproic acid, metformin, dichloroacetate,
      cigarettes, and alcohol.

📚

References & Deep Research

References

1

PMID:20301411

MELAS.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes): Disease Characteristics Research Report

Edison Scientific Literature 38 citations 2026-06-08T17:21:58.348453

MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes): Disease Characteristics Research Report

Executive summary

MELAS syndrome is a maternally inherited mitochondrial disorder, classically defined by mitochondrial encephalopathy, lactic acidosis, and recurrent stroke-like episodes (SLEs). It is most commonly caused by heteroplasmic mtDNA variants affecting mitochondrial tRNA genes, especially MT-TL1 m.3243A>G (~80% of cases in multiple contemporary reviews/cohorts). Clinical presentation is multisystemic, but neurologic manifestations (SLEs, seizures, cognitive decline) dominate morbidity and mortality. Recent population-based epidemiology (2024) and large “clinically unselected” genomics (2024) have refined prevalence/incidence and penetrance estimates, supporting genotype/heteroplasmy-stratified risk assessment. Therapeutics remain largely supportive; the strongest interventional evidence in MELAS-specific SLE prevention includes high-dose taurine (open-label phase III trial) and systematic L-arginine regimens (prospective multicenter), with ongoing clinical trials targeting redox/bioenergetics.

1. Disease information

1.1 What is the disease? (overview and definition)

MELAS is a rare mitochondrial syndrome characterized by encephalopathy, lactic acidosis, and stroke-like episodes (SLEs) with non-vascular-distribution brain lesions that may shift over time. Reviews emphasize its broad systemic manifestations (neurologic, muscular, endocrine, cardiac, renal), but recurrent SLEs and seizures are key clinical drivers of disability. (na2024diagnosisandmanagement pages 1-2, na2024diagnosisandmanagement pages 8-9)

Abstract-quotable definition (recent cohort/review): - Xu et al. (Orphanet J Rare Dis, 2024-12, DOI: 10.1186/s13023-024-03511-4) describes MELAS as “Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes,” a maternally inherited mitochondrial disorder affecting primarily the CNS and skeletal muscle. (xu2024multisystemclinicopathologicand pages 1-2)

1.2 Key identifiers

Available in retrieved evidence - OMIM: #540000 (explicitly stated in Xu et al. 2024). (xu2024multisystemclinicopathologicand pages 1-2)

Not found in retrieved evidence (should be confirmed from external disease ontologies/databases): - Orphanet (ORPHA), ICD-10/ICD-11, MeSH, MONDO.

1.3 Synonyms and alternative names

“Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes” (expansion of MELAS) (na2024diagnosisandmanagement pages 1-2)
“Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes” (common spelling variant) (ohsawa2019taurinesupplementationfor pages 1-2)

1.4 Evidence provenance (individual patients vs disease resources)

Evidence used here is derived from: - Aggregated disease-level resources: narrative reviews (e.g., Na & Lee 2024). (na2024diagnosisandmanagement pages 1-2) - Human clinical cohorts/registries: imaging cohorts (Zheng 2023), multisystem retrospective cohorts (Xu 2024; Cox 2023), and population-based epidemiology (Martikainen 2024). (zheng2023mitochondrialencephalomyopathywith pages 1-2, xu2024multisystemclinicopathologicand pages 1-2, cox2023theclinicalspectrum pages 1-2, martikainen2024incidenceandprevalence pages 1-2) - Interventional clinical trials: taurine phase III open-label trial; idebenone randomized trial; ClinicalTrials.gov interventional studies. (ohsawa2019taurinesupplementationfor pages 1-2, NCT00887562 chunk 1)

2. Etiology

2.1 Disease causal factors

Genetic (primary): MELAS is most commonly due to pathogenic mtDNA variants affecting mitochondrial translation, especially heteroplasmic MT-TL1 m.3243A>G, repeatedly cited as accounting for ~80% of MELAS cases. (na2024diagnosisandmanagement pages 7-8, xu2024multisystemclinicopathologicand pages 1-2)

Other mtDNA variants associated with MELAS include MT-ND5 (e.g., m.13513G>A, ~10–15% in one 2024 review) and other tRNA gene variants (e.g., MT-TH, MT-TK), plus rarer MT-TL1 variants (e.g., m.3271T>C). (na2024diagnosisandmanagement pages 7-8)

Mechanistic causal chain (current understanding): - Pathogenic mtDNA variants impair mitochondrial protein synthesis → defective oxidative phosphorylation (OXPHOS) → cellular energy failure and lactate accumulation. (na2024diagnosisandmanagement pages 7-8) - Stroke-like episodes are non-vascular and are hypothesized to involve multiple interacting mechanisms including mitochondrial angiopathy/vasculopathy, mitochondrial cytopathy, and neuronal excitotoxicity. (zheng2023mitochondrialencephalomyopathywith pages 1-2, xu2024multisystemclinicopathologicand pages 1-2)

2.2 Risk factors

Genetic risk factors - Presence of heteroplasmic pathogenic mtDNA variants, especially m.3243A>G, with higher heteroplasmy generally associated with greater multisystem risk. - In UK Biobank WGS, multi-system disease risk and penetrance for diabetes/deafness/heart failure increased substantially when m.3243A>G heteroplasmy reached ≥10% (see Section 9). (cannon2024penetranceandexpressivity pages 1-2)

Environmental/physiologic risk factors (evidence-limited in retrieved texts): - Episodes may be precipitated by physiologic stressors (infections, metabolic decompensation), but specific quantified environmental triggers were not systematically captured in the retrieved evidence.

2.3 Protective factors

No validated genetic “protective variants” were identified in the retrieved evidence. Nonetheless, Cannon et al. suggests that penetrance of most pathogenic mtDNA variants is low in unselected populations (exception m.3243A>G at higher heteroplasmy), implying that host genetic background (including polygenic risk) can modify expression. (cannon2024penetranceandexpressivity pages 1-2)

2.4 Gene–environment / gene–gene interactions

Cannon et al. (Human Mol Genet, 2024-11, DOI: 10.1093/hmg/ddad194) reports that diabetes risk with m.3243A>G was further influenced by type 2 diabetes genetic risk, supporting gene–gene interaction between mtDNA heteroplasmy and nuclear polygenic susceptibility. (cannon2024penetranceandexpressivity pages 1-2)

3. Phenotypes

3.1 Core phenotype spectrum (with frequencies where available)

A concise frequency summary (from a phenotype-focused review letter) reports: - SLEs: >90% - Seizures: 76% - Headache: 50% - Vomiting: 55% - Visual loss: 52% - Muscle weakness: 48% - Short stature: >25% - Diabetes: 10–24% These estimates should be interpreted cautiously because they are compiled narrative frequencies rather than from a single prospective cohort. (finsterer2020rarephenotypicmanifestations pages 1-2)

A 2023 large retrospective cohort spanning MELAS to asymptomatic carriers reported: - Seizures in MELAS: 88.1% (vs 16.7% in symptomatic non-MELAS). (cox2023theclinicalspectrum pages 1-2) - Late-onset MELAS had high diabetes (69.2%) and nephropathy (53.8%), suggesting phenotype shifts with age at first SLE. (cox2023theclinicalspectrum pages 1-2)

3.2 Phenotype characteristics (onset, severity, progression)

SLEs are typically before age 40 in classic MELAS definitions; location of lesions can shift over time and does not respect vascular territories. (na2024diagnosisandmanagement pages 7-8, na2024diagnosisandmanagement pages 8-9)
Disease course is progressive with recurrent neurological events contributing to reduced life expectancy. (na2024diagnosisandmanagement pages 1-2)

3.3 Quality-of-life impact

Quantitative QoL instruments (e.g., SF-36, EQ-5D, PROMIS) were not reported in the retrieved evidence. Functional outcomes, however, were captured via modified Rankin Scale (mRS) distributions in a 2024 cohort (Section 11). (gao2024longtermprognosticfactors pages 1-2)

3.4 Suggested HPO terms

A phenotype-to-HPO mapping table is provided below.

MELAS clinical feature	Suggested HPO term	HP ID	Frequency / onset notes	Evidence source
Stroke-like episodes	Stroke-like episode	HP:0002401	>90% of patients in Finsterer 2020; typically a core feature of MELAS, often before age 40 in classic diagnostic criteria; all 39 patients in Gao 2024 initially presented with stroke-like episodes	(finsterer2020rarephenotypicmanifestations pages 1-2, gao2024longtermprognosticfactors pages 1-2)
Seizures	Seizure	HP:0001250	76% in Finsterer 2020; 88.1% in MELAS group in Cox 2023	(finsterer2020rarephenotypicmanifestations pages 1-2, cox2023theclinicalspectrum pages 1-2)
Lactic acidosis	Lactic acidosis	HP:0003128	Hallmark biochemical abnormality; elevated plasma/CSF lactate and lactate peak on MRS; not quantified in retrieved evidence for symptom frequency	(na2024diagnosisandmanagement pages 7-8, na2024diagnosisandmanagement pages 8-9)
Migraine / headache	Headache	HP:0002315	Headache 50% in Finsterer 2020; recurrent headache is also part of classic diagnostic criteria; migraine-like headache reported in MELAS cohorts	(finsterer2020rarephenotypicmanifestations pages 1-2, elhattab2017arginineandcitrulline pages 1-2)
Vomiting	Vomiting	HP:0002013	55% in Finsterer 2020; recurrent vomiting is part of classic diagnostic criteria	(finsterer2020rarephenotypicmanifestations pages 1-2, elhattab2017arginineandcitrulline pages 1-2)
Muscle weakness / myopathy / exercise intolerance	Proximal muscle weakness / Mitochondrial myopathy / Exercise intolerance	HP:0003701 / HP:0003200 / HP:0003546	Muscle weakness 48% in Finsterer 2020; proximal muscle weakness and exercise intolerance were predominant in Xu 2024 cohort; onset variable, often childhood to young adulthood	(finsterer2020rarephenotypicmanifestations pages 1-2, xu2024multisystemclinicopathologicand pages 1-2)
Sensorineural hearing loss	Sensorineural hearing impairment	HP:0000407	Diabetes and deafness associated with intermediate heteroplasmy (about 50–70%) in Na 2024; hearing loss was the first symptom in 51.6% of symptomatic non-MELAS vs 24.4% of MELAS in Cox 2023; exact overall MELAS frequency not quantified in retrieved evidence	(na2024diagnosisandmanagement pages 7-8, cox2023theclinicalspectrum pages 1-2)
Diabetes mellitus	Diabetes mellitus	HP:0000819	Reported in 10–24% in Finsterer 2020; late-onset MELAS had diabetes in 69.2% vs 13.8% standard-onset in Cox 2023	(finsterer2020rarephenotypicmanifestations pages 1-2, cox2023theclinicalspectrum pages 1-2)
Short stature	Short stature	HP:0004322	>25% of cases in Finsterer 2020	(finsterer2020rarephenotypicmanifestations pages 1-2)
Cortical blindness / vision loss	Cortical visual impairment / Cortical blindness	HP:0100704 / HP:0007956	Visual loss 52% in Finsterer 2020; cortical vision loss listed as a typical phenotype in Na 2024; vision loss in first stroke-like episode helped define atypical MELAS in Alves 2023 summary	(finsterer2020rarephenotypicmanifestations pages 1-2, na2024diagnosisandmanagement pages 8-9)
Cerebellar atrophy	Cerebellar atrophy	HP:0001272	68% (40/59 imaging studies) in Zheng 2023; also highly discriminatory for stroke-like episodes vs acute ischemic stroke in Khasminsky 2023	(zheng2023mitochondrialencephalomyopathywith pages 1-2, khasminsky2023clinicoradiologiccriteriafor pages 1-2)
Basal ganglia calcification	Basal ganglia calcification	HP:0002135	67% (6/9 patients with CT) in Zheng 2023	(zheng2023mitochondrialencephalomyopathywith pages 1-2)

Table: This table maps core MELAS manifestations to suggested Human Phenotype Ontology terms and summarizes frequency or onset information from the retrieved evidence. It is useful for structured phenotype curation in a disease knowledge base.

4. Genetic / molecular information

4.1 Causal genes

Primary causal locus (mtDNA): - MT-TL1 (mitochondrially encoded tRNA leucine 1) with canonical m.3243A>G heteroplasmic variant. (na2024diagnosisandmanagement pages 7-8, xu2024multisystemclinicopathologicand pages 1-2)

Other mtDNA genes/regions implicated (not exhaustive; examples from retrieved evidence): - MT-ND5 (including m.13513G>A), MT-TH, MT-TK, and other tRNA genes; additional variants reported in one 2024 cohort include m.5628T>C, m.6352-13952del, and 9-bp deletions combined with m.3243A>G. (na2024diagnosisandmanagement pages 7-8, xu2024multisystemclinicopathologicand pages 1-2)

4.2 Pathogenic variants and heteroplasmy

m.3243A>G is typically heteroplasmic, and clinical severity varies with tissue mutation load (threshold effect) and tissue distribution; one 2024 review summarizes that higher mutant load is often found in muscle/urine than blood. (na2024diagnosisandmanagement pages 7-8)
In a large clinically unselected cohort, higher m.3243A>G heteroplasmy (≥10%) was associated with markedly increased odds of diabetes, deafness, and heart failure. (cannon2024penetranceandexpressivity pages 1-2)

4.3 Modifier genes / nuclear factors

Direct nuclear “modifier genes” were not extracted from the retrieved texts. However, polygenic type 2 diabetes genetic risk modified diabetes risk in m.3243A>G carriers. (cannon2024penetranceandexpressivity pages 1-2)

4.4 Epigenetic and chromosomal abnormalities

No MELAS-specific epigenetic or chromosomal abnormality evidence was found in the retrieved texts.

5. Environmental information

Specific toxins, lifestyle exposures, or infectious triggers were not systematically quantified in the retrieved evidence. Physiological stressors are commonly discussed in case reports and reviews but are outside the evidence captured here.

6. Mechanism / pathophysiology

6.1 Molecular pathways and cellular processes

Upstream driver: impaired mitochondrial translation and OXPHOS defect → ATP deficit and lactate accumulation (systemic and cerebral). (na2024diagnosisandmanagement pages 7-8)

Stroke-like episode mechanisms (multiple interacting hypotheses): - Mitochondrial vasculopathy/angiopathy: microvascular dysfunction and impaired perfusion; NO deficiency is a prominent mechanistic hypothesis supporting arginine/citrulline therapy. (xu2024multisystemclinicopathologicand pages 1-2, elhattab2017arginineandcitrulline pages 1-2) - Mitochondrial cytopathy: direct neuronal/glial energy failure. (zheng2023mitochondrialencephalomyopathywith pages 1-2) - Neuronal excitotoxicity / hyperexcitability: implicated by seizure association and some imaging/clinical patterns. (zheng2023mitochondrialencephalomyopathywith pages 1-2)

6.2 Metabolic changes and biochemical abnormalities

Lactic acidosis and MRS lactate: - Proton MRS commonly shows elevated lactate peaks; e.g., in an m.3243A>G imaging cohort, lactate peaks were present in 9/10 (90%) measured cases. (zheng2023mitochondrialencephalomyopathywith pages 1-2)

31P-MRS (energetics signature): - A 2024 multisystem cohort reports abnormal Pi/PCr ratios on 31P-MRS, consistent with disturbed high-energy phosphate metabolism. (xu2024multisystemclinicopathologicand pages 1-2)

6.3 “Omics” and molecular profiling

No transcriptomic/proteomic/metabolomic multi-omics datasets specific to MELAS were retrieved here. Metabolic profiling proxies available include 1H-MRS and 31P-MRS energetics measures. (xu2024multisystemclinicopathologicand pages 1-2, zheng2023mitochondrialencephalomyopathywith pages 1-2)

6.4 Suggested ontology terms for mechanisms

GO Biological Process (suggestions; ontology IDs should be confirmed against GO): - Mitochondrial translation; oxidative phosphorylation; ATP metabolic process; response to oxidative stress; regulation of cerebral blood flow; excitatory synaptic transmission.

Cell Ontology (CL) cell types implicated (suggestions): - Cerebral vascular endothelial cell; neuron; astrocyte; skeletal muscle fiber.

7. Anatomical structures affected

7.1 Organ/system level

Commonly involved systems include: - Central nervous system (stroke-like lesions, seizures, progressive decline). (na2024diagnosisandmanagement pages 1-2) - Skeletal muscle (myopathy, weakness, exercise intolerance). (na2024diagnosisandmanagement pages 1-2, xu2024multisystemclinicopathologicand pages 1-2) - Endocrine/metabolic (diabetes). (na2024diagnosisandmanagement pages 1-2, cox2023theclinicalspectrum pages 1-2) - Cardiac (hypertrophic cardiomyopathy/arrhythmias noted in reviews; heart failure association in population genomics). (na2024diagnosisandmanagement pages 8-9, cannon2024penetranceandexpressivity pages 1-2) - Renal (nephropathy in late-onset phenotype). (cox2023theclinicalspectrum pages 1-2)

7.2 Tissue/cell and subcellular level

Mitochondria (subcellular compartment) are central; muscle biopsy may show ragged red fibers and COX-defective fibers indicating mitochondrial proliferation and respiratory chain dysfunction. (xu2024multisystemclinicopathologicand pages 1-2, na2024diagnosisandmanagement pages 8-9)

7.3 Neuroanatomical localization patterns (quantitative imaging)

A 2023 imaging analysis of m.3243A>G MELAS reported predominant posterior cortical involvement: - Occipital: 63% (37/59) - Parietal: 54% (32/59) - Temporal: 51% (30/59) with frequent atrophy and lesion polymorphism; see quantitative table below. (zheng2023mitochondrialencephalomyopathywith pages 1-2)

8. Temporal development

8.1 Onset

Classic MELAS definitions emphasize early-onset stroke-like episodes (often before age 40). (elhattab2017arginineandcitrulline pages 1-2, na2024diagnosisandmanagement pages 7-8)
A 2023 cohort distinguished “standard-onset” (first SLE <40) versus late-onset; late-onset cases had longer prodromal periods and died later (mean age at death 62 vs 30). (cox2023theclinicalspectrum pages 1-2)

8.2 Progression and course

Disease course is typically progressive with episodic neurologic decompensation (SLEs, status epilepticus) and accumulating deficits. (na2024diagnosisandmanagement pages 1-2, gao2024longtermprognosticfactors pages 1-2)

9. Inheritance and population

9.1 Inheritance

Mitochondrial (maternal) inheritance is a defining property; heteroplasmy and tissue distribution create variable expressivity and incomplete penetrance. (na2024diagnosisandmanagement pages 7-8, xu2024multisystemclinicopathologicand pages 1-2)

9.2 Epidemiology (recent data prioritized)

A 2024 observational population-based study in Southwest Finland reported adult mtDNA disease epidemiology that can serve as a modern benchmark (not MELAS-specific only, but includes m.3243A>G-related disease): - Adult mtDNA disease prevalence (2022): 9.2/100,000 (95% CI 6.5–12.7). (martikainen2024incidenceandprevalence pages 1-2) - Adult m.3243A>G-related disease prevalence: 4.2/100,000 (95% CI 2.5–6.7). (martikainen2024incidenceandprevalence pages 1-2) - Annual incidence (2010–2022): adult mtDNA disease 0.6/100,000; adult m.3243A>G-related disease 0.3/100,000. (martikainen2024incidenceandprevalence pages 1-2) The authors explicitly note that improved diagnostics and dedicated ascertainment increase detection, and that under-recognition of oligosymptomatic cases is likely. (martikainen2024incidenceandprevalence pages 2-3, martikainen2024incidenceandprevalence pages 3-4)

9.3 Penetrance and expressivity (2024 large unselected cohort)

In UK Biobank WGS, Cannon et al. showed: - Most pathogenic mtDNA variants had low penetrance in unselected populations, except m.3243A>G. (cannon2024penetranceandexpressivity pages 1-2) - When m.3243A>G heteroplasmy ≥10%, odds ratios increased markedly: - Diabetes OR: 5.61 → 25.1 - Deafness OR: 12.3 → 55.0 - Heart failure OR: 10.1 → 39.5 This supports quantitative heteroplasmy thresholds for clinical risk stratification and incidental reporting discussions. (cannon2024penetranceandexpressivity pages 1-2)

10. Diagnostics

10.1 Clinical and biochemical tests

Common diagnostic elements include: - Lactic acidosis (plasma and/or CSF lactate/pyruvate) and lactate peaks on MRS. (na2024diagnosisandmanagement pages 8-9) - Neuroimaging: cortical/subcortical lesions not respecting vascular territories; lesions may shift over time. (na2024diagnosisandmanagement pages 8-9) - Muscle biopsy (when genetic testing inconclusive): ragged red fibers (RRF) and COX-defective fibers may support diagnosis. (xu2024multisystemclinicopathologicand pages 1-2)

10.2 Genetic testing

Genetic diagnosis commonly relies on mtDNA testing to identify causative variants and measure heteroplasmy. A 2024 review notes tissue heteroplasmy differences (muscle/urine often higher than blood), implying that multi-tissue testing improves sensitivity. (na2024diagnosisandmanagement pages 7-8)

10.3 Clinicoradiologic criteria for stroke-like episodes (SLE) (real-world implementation)

Stroke-like episodes are frequently misdiagnosed as acute ischemic stroke. A 2023 Neurology Genetics study derived and validated pragmatic criteria and an algorithm using clinical history and CT/CTA patterns: - “Possible SLE” criteria: sensitivity 100%, specificity 81% (AUC 0.905). - “Probable SLE” criteria: sensitivity 88%, specificity 95% (AUC 0.917). (khasminsky2023clinicoradiologiccriteriafor pages 1-2)

Visual evidence (Table and diagnostic algorithm): (khasminsky2023clinicoradiologiccriteriafor media eef69170, khasminsky2023clinicoradiologiccriteriafor media 6adc2877)

11. Outcome / prognosis

11.1 Survival and mortality (cohort evidence)

In one 2023 retrospective spectrum cohort, MELAS showed 50% mortality at 25 years from onset (comparison group 10%). (cox2023theclinicalspectrum pages 1-2)

11.2 Functional outcomes and prognostic markers (2024 cohort)

A 2024 retrospective cohort (n=39; mean follow-up 7.3±4.7 years) reported: - Deaths: 8/39, primarily due to acute SLEs and status epilepticus. (gao2024longtermprognosticfactors pages 1-2) - mRS distribution: 41% (0–2), 38.5% (3–5), 20.5% (6 or died). (gao2024longtermprognosticfactors pages 1-2) - Independent mortality predictors: - Severe lactate elevation OR 7.279 (95% CI 1.102–48.086) - Anemia associated with poor prognosis (reported OR 0.137 with CI 0.021–0.908; directionality in the paper indicates anemia as an adverse prognostic factor). (gao2024longtermprognosticfactors pages 1-2)

12. Treatment

12.1 Current standard of care (supportive)

A 2024 management review describes MELAS care as largely supportive, including anti-seizure medications, metabolic supplementation (arginine/citrulline, high-dose taurine), and dietary therapies. (na2024diagnosisandmanagement pages 1-2)

A practical dosing example from the same review for commonly used mitochondrial cofactors includes: - CoQ10: “typically” 30 mg/kg/day - Riboflavin: 50–400 mg daily - L-carnitine: 50–100 mg/kg/day These are supportive and not disease-modifying for the mtDNA defect. (na2024diagnosisandmanagement pages 8-9)

MAXO (treatment action) suggestions (confirm in MAXO): - Intravenous amino acid supplementation (L-arginine) - Oral amino acid supplementation (L-arginine; L-citrulline) - Taurine supplementation - Antiseizure therapy - Nutritional therapy / dietary intervention

12.2 Targeted symptomatic/preventive therapies for SLEs

Taurine (high-dose oral)

A multicenter open-label phase III trial in 10 patients with recurrent SLEs administered 9 g/day or 12 g/day taurine for 52 weeks: - Primary endpoint (complete prevention): 60% (95% CI 26.2–87.8) - ≥50% reduction responder rate: 80% (95% CI 44.4–97.5) - Annual relapse rate reduced 2.22 → 0.72 (P=0.001) - No severe adverse events attributed to taurine. (ohsawa2019taurinesupplementationfor pages 1-2) Mechanistically, the trial frames MELAS as a “tRNA modification disorder” in which taurine corrects defective taurine modification of mitochondrial tRNALeu(UUR), improving decoding fidelity. (ohsawa2019taurinesupplementationfor pages 1-2)

L-arginine (acute and prophylactic regimens)

A 9-year prospective multicenter Japanese clinical research program tested systematic oral and IV L-arginine: - Oral: 0.3–0.5 g/kg/day for 2 years - IV: 0.5 g/kg per dose (acute ictus regimen) - Observed benefits included decreased incidence/severity of ictuses and improvement in acute symptoms (headache, nausea/vomiting, impaired consciousness, visual disturbance) with favorable tolerability. (koga2018therapeuticregimenof pages 1-2) A 2022 systematic review synthesizing small trials reported decreases in stroke-like episode frequency and severity scores with oral prophylaxis, and symptomatic improvements with IV arginine. (argudo2022arginineforthe pages 4-5)

Citrulline

Citrulline is discussed as a nitric oxide precursor potentially increasing NO production more robustly than arginine; however, clinical efficacy studies were noted as limited in older reviews. (elhattab2017arginineandcitrulline pages 1-2)

12.3 Experimental / emerging therapies (pipeline)

A 2024 review describes experimental directions such as gene therapy and mitochondrial replacement techniques, along with redox/mitochondrial-targeted candidates. (na2024diagnosisandmanagement pages 1-2, na2024diagnosisandmanagement pages 12-14)

13. Prevention

Primary prevention of MELAS itself is genetic (maternal transmission risk reduction). The retrieved evidence mentions mitochondrial replacement therapy conceptually as a preventive reproductive strategy (without clinical outcome data in the retrieved excerpts). (na2024diagnosisandmanagement pages 12-14)

Secondary/tertiary prevention focuses on preventing or mitigating SLEs and seizures: - Taurine prophylaxis and arginine/citrulline strategies are used to reduce SLE frequency/severity. (ohsawa2019taurinesupplementationfor pages 1-2, koga2018therapeuticregimenof pages 1-2)

14. Other species / natural disease

No naturally occurring MELAS analogs in non-human species were identified in the retrieved evidence.

15. Model organisms

No animal or cellular model organism resources were identified in the retrieved evidence.

Quantitative evidence summary table

Domain	Finding (with numbers)	Study/source	Publication date	URL/DOI	Evidence type	Notes
Common causal variant	MT-TL1 m.3243A>G accounts for ~80% of MELAS cases	Na & Lee, Biomolecules; Xu et al., Orphanet J Rare Dis (na2024diagnosisandmanagement pages 7-8, xu2024multisystemclinicopathologicand pages 1-2)	2024-11; 2024-12	https://doi.org/10.3390/biom14121524; https://doi.org/10.1186/s13023-024-03511-4	Review; retrospective cohort	Xu reports OMIM #540000; Xu cohort n=29
Neuroimaging lesion distribution	Posterior brain predominance: occipital 37/59 (63%), parietal 32/59 (54%), temporal 30/59 (51%); lesion polymorphism 37/59 (63%); cerebral atrophy 38/59 (64%); cerebellar atrophy 40/59 (68%); basal ganglia calcification 6/9 (67%); MRS lactate peak 9/10 (90%); arterial dilation 4/6 (67%)	Zheng et al., Front Neurosci (zheng2023mitochondrialencephalomyopathywith pages 1-2)	2023-01	https://doi.org/10.3389/fnins.2022.1028762	Retrospective imaging cohort	59 imaging studies in 24 genetically confirmed m.3243A>G patients
Prognostic markers	Mean follow-up 7.3 ± 4.7 years; deaths 8/39; severe lactate elevation predicted mortality: OR 7.279 (95% CI 1.102–48.086, p=0.039); anemia associated with poor prognosis: OR 0.137 (95% CI 0.021–0.908, p=0.039); lactate vs mRS r=0.460 (p=0.003); hemoglobin vs mRS r=-0.375 (p=0.015)	Gao et al., Front Neurol (gao2024longtermprognosticfactors pages 1-2)	2024-12	https://doi.org/10.3389/fneur.2024.1491283	Retrospective cohort	Single-center MELAS cohort n=39; all initially presented with stroke-like episodes
Phenotype frequencies and survival	Seizures in MELAS 88.1% vs 16.7% in symptomatic non-MELAS; sensorineural hearing loss as first symptom 51.6% in symptomatic non-MELAS vs 24.4% in MELAS; mean serum heteroplasmy 39.3% (MELAS) vs 29.3% (symptomatic non-MELAS) vs 21.8% (asymptomatic); 50% mortality at 25 years in MELAS vs 10% comparison group; late-onset MELAS: diabetes 69.2%, nephropathy 53.8%	Cox et al., Front Neurol (cox2023theclinicalspectrum pages 1-2)	2023-12	https://doi.org/10.3389/fneur.2023.1298569	Retrospective cohort	Overall n=81: 42 MELAS, 30 symptomatic non-MELAS, 9 asymptomatic; 13 late-onset MELAS
Taurine trial outcomes	High-dose taurine 9 g/day or 12 g/day for 52 weeks; 100% responder rate 60% (95% CI 26.2–87.8); ≥50% responder rate 80% (95% CI 44.4–97.5); annual relapse rate reduced 2.22 to 0.72 (P=0.001); no severe adverse events	Ohsawa et al., J Neurol Neurosurg Psychiatry (khasminsky2023clinicoradiologiccriteriafor media eef69170, khasminsky2023clinicoradiologiccriteriafor media 6adc2877)	2019-04	https://doi.org/10.1136/jnnp-2018-317964	Multicentre open-label phase III trial	n=10 with recurrent stroke-like episodes; trial registration UMIN000011908
Population-based prevalence/incidence	Adult mtDNA-related mitochondrial disease prevalence 9.2/100,000 (95% CI 6.5–12.7) in 2022; adult m.3243A>G-related disease prevalence 4.2/100,000 (95% CI 2.5–6.7); annual incidence of adult mtDNA disease 0.6/100,000; annual incidence of adult m.3243A>G-related disease 0.3/100,000	Martikainen & Majamaa, BMJ Neurol Open (cox2023theclinicalspectrum pages 1-2)	2024-02	https://doi.org/10.1136/bmjno-2023-000546	Population-based observational study	Southwest Finland, 2009–2022; 42 new adult patients diagnosed; mean 3.2 new diagnoses/year

Table: This table compiles key quantitative findings on MELAS syndrome from recent and landmark studies, including genetics, imaging, prognosis, phenotype burden, treatment outcomes, and population epidemiology. It is useful as a compact evidence summary for knowledge base curation and report drafting.

Real-world implementations and clinical trials (selected)

Recent and active clinical research is visible in ClinicalTrials.gov records: - NCT01339494 (completed; Early Phase 1; n=30): oral L-arginine and L-citrulline (10 g/m²/day divided q4h for 48 h each) with primary outcome change in nitric oxide production; includes patients with m.3243A>G. (NCT01339494 chunk 1) - NCT03952234 (completed; Phase 1; n=10): L-citrulline dose-finding in adults with MELAS and m.3243A>G; primary outcome maximum tolerable dose / DLTs over 8 weeks. (NCT03952234 chunk 1) - NCT00887562 (completed; Phase IIa; randomized, placebo-controlled; n=27): idebenone 900 or 2250 mg/day for 1 month; primary outcome change in cerebral lactate by MRS. (NCT00887562 chunk 1) - NCT06644534 (recruiting; Phase 2; planned n=12): TTI-0102 (cysteamine-pantetheine disulfide) vs placebo; primary outcomes include 12-minute walk test change and safety; inclusion requires MELAS-associated mtDNA variants with heteroplasmy thresholds and clinical features including stroke-like episodes. (NCT06644534 chunk 1)

Limitations of this evidence package (important for knowledge base curation)

PMIDs were not present in the retrieved excerpts for many sources; therefore, PMID-level citation could not be systematically provided despite the user preference. DOIs/URLs and publication dates are provided whenever available in the retrieved evidence.
Orphanet/ICD/MeSH/MONDO codes were not explicitly captured in the retrieved texts, except OMIM #540000 from Xu 2024; these should be supplemented by direct lookup in OMIM/Orphanet/MONDO/MeSH.
Multi-omics (transcriptomics/proteomics/metabolomics) MELAS datasets were not retrieved in this run; only MRS-based metabolic profiling proxies were available.

References

(na2024diagnosisandmanagement pages 1-2): Ji-Hoon Na and Young-Mock Lee. Diagnosis and management of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. Biomolecules, 14:1524, Nov 2024. URL: https://doi.org/10.3390/biom14121524, doi:10.3390/biom14121524. This article has 29 citations.
(na2024diagnosisandmanagement pages 8-9): Ji-Hoon Na and Young-Mock Lee. Diagnosis and management of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. Biomolecules, 14:1524, Nov 2024. URL: https://doi.org/10.3390/biom14121524, doi:10.3390/biom14121524. This article has 29 citations.
(xu2024multisystemclinicopathologicand pages 1-2): Shuai Xu, Jialiu Jiang, Leilei Chang, Biao Zhang, Xiaolei Zhu, and Fengnan Niu. Multisystem clinicopathologic and genetic analysis of melas. Orphanet Journal of Rare Diseases, Dec 2024. URL: https://doi.org/10.1186/s13023-024-03511-4, doi:10.1186/s13023-024-03511-4. This article has 8 citations and is from a peer-reviewed journal.
(ohsawa2019taurinesupplementationfor pages 1-2): Yutaka Ohsawa, Hiroki Hagiwara, Shin-ichiro Nishimatsu, Akihiro Hirakawa, Naomi Kamimura, Hideaki Ohtsubo, Yuta Fukai, Tatsufumi Murakami, Yasutoshi Koga, Yu-ichi Goto, Shigeo Ohta, and Yoshihide Sunada. Taurine supplementation for prevention of stroke-like episodes in melas: a multicentre, open-label, 52-week phase iii trial. Journal of Neurology, Neurosurgery, and Psychiatry, 90:529-536, Apr 2019. URL: https://doi.org/10.1136/jnnp-2018-317964, doi:10.1136/jnnp-2018-317964. This article has 171 citations.
(zheng2023mitochondrialencephalomyopathywith pages 1-2): Helin Zheng, Xuemei Zhang, Lu Tian, Bo Liu, Xiaoya He, Longlun Wang, Shuang Ding, Yi Guo, and Jinhua Cai. Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes with an mt-tl1 m.3243a>g point mutation: neuroradiological features and their implications for underlying pathogenesis. Frontiers in Neuroscience, Jan 2023. URL: https://doi.org/10.3389/fnins.2022.1028762, doi:10.3389/fnins.2022.1028762. This article has 14 citations and is from a peer-reviewed journal.
(cox2023theclinicalspectrum pages 1-2): Benjamin C. Cox, Jennifer Y. Pearson, Jay Mandrekar, and Ralitza H. Gavrilova. The clinical spectrum of melas and associated disorders across ages: a retrospective cohort study. Frontiers in Neurology, Dec 2023. URL: https://doi.org/10.3389/fneur.2023.1298569, doi:10.3389/fneur.2023.1298569. This article has 17 citations and is from a peer-reviewed journal.
(martikainen2024incidenceandprevalence pages 1-2): Mika H Martikainen and Kari Majamaa. Incidence and prevalence of mtdna-related adult mitochondrial disease in southwest finland, 2009–2022: an observational, population-based study. BMJ Neurology Open, 6:e000546, Feb 2024. URL: https://doi.org/10.1136/bmjno-2023-000546, doi:10.1136/bmjno-2023-000546. This article has 9 citations and is from a peer-reviewed journal.
(NCT00887562 chunk 1): Michio Hirano. Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes. Michio Hirano. 2009. ClinicalTrials.gov Identifier: NCT00887562
(na2024diagnosisandmanagement pages 7-8): Ji-Hoon Na and Young-Mock Lee. Diagnosis and management of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. Biomolecules, 14:1524, Nov 2024. URL: https://doi.org/10.3390/biom14121524, doi:10.3390/biom14121524. This article has 29 citations.
(cannon2024penetranceandexpressivity pages 1-2): Stuart J Cannon, Timothy Hall, Gareth Hawkes, Kevin Colclough, Roisin M Boggan, Caroline F Wright, Sarah J Pickett, Andrew T Hattersley, Michael N Weedon, and Kashyap A Patel. Penetrance and expressivity of mitochondrial variants in a large clinically unselected population. Human Molecular Genetics, 33:465-474, Nov 2024. URL: https://doi.org/10.1093/hmg/ddad194, doi:10.1093/hmg/ddad194. This article has 15 citations and is from a domain leading peer-reviewed journal.
(finsterer2020rarephenotypicmanifestations pages 1-2): Josef Finsterer. Rare phenotypic manifestations of melas. Yonsei Medical Journal, 61:904-906, Sep 2020. URL: https://doi.org/10.3349/ymj.2020.61.10.904, doi:10.3349/ymj.2020.61.10.904. This article has 5 citations and is from a peer-reviewed journal.
(gao2024longtermprognosticfactors pages 1-2): Rui Gao, Lihua Gu, Wenchao Zuo, and Pan Wang. Long-term prognostic factors and outcomes in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes: a clinical and biochemical marker analysis. Frontiers in Neurology, Dec 2024. URL: https://doi.org/10.3389/fneur.2024.1491283, doi:10.3389/fneur.2024.1491283. This article has 7 citations and is from a peer-reviewed journal.
(elhattab2017arginineandcitrulline pages 1-2): Ayman W. El-Hattab, Mohammed Almannai, and Fernando Scaglia. Arginine and citrulline for the treatment of melas syndrome. Journal of inborn errors of metabolism and screening, 5:232640981769739, Mar 2017. URL: https://doi.org/10.1177/2326409817697399, doi:10.1177/2326409817697399. This article has 79 citations.
(khasminsky2023clinicoradiologiccriteriafor pages 1-2): Vadim Khasminsky, Eitan Auriel, Judith Luckman, Ruth Eliahou, Edna Inbar, Keshet Pardo, Yuval Landau, Rani Barnea, Maor Mermelstein, Shahar Shelly, Jonathan Naftali, and Shlomi Peretz. Clinicoradiologic criteria for the diagnosis of stroke-like episodes in melas. Aug 2023. URL: https://doi.org/10.1212/nxg.0000000000200082, doi:10.1212/nxg.0000000000200082. This article has 10 citations.
(martikainen2024incidenceandprevalence pages 2-3): Mika H Martikainen and Kari Majamaa. Incidence and prevalence of mtdna-related adult mitochondrial disease in southwest finland, 2009–2022: an observational, population-based study. BMJ Neurology Open, 6:e000546, Feb 2024. URL: https://doi.org/10.1136/bmjno-2023-000546, doi:10.1136/bmjno-2023-000546. This article has 9 citations and is from a peer-reviewed journal.
(martikainen2024incidenceandprevalence pages 3-4): Mika H Martikainen and Kari Majamaa. Incidence and prevalence of mtdna-related adult mitochondrial disease in southwest finland, 2009–2022: an observational, population-based study. BMJ Neurology Open, 6:e000546, Feb 2024. URL: https://doi.org/10.1136/bmjno-2023-000546, doi:10.1136/bmjno-2023-000546. This article has 9 citations and is from a peer-reviewed journal.
(khasminsky2023clinicoradiologiccriteriafor media eef69170): Vadim Khasminsky, Eitan Auriel, Judith Luckman, Ruth Eliahou, Edna Inbar, Keshet Pardo, Yuval Landau, Rani Barnea, Maor Mermelstein, Shahar Shelly, Jonathan Naftali, and Shlomi Peretz. Clinicoradiologic criteria for the diagnosis of stroke-like episodes in melas. Aug 2023. URL: https://doi.org/10.1212/nxg.0000000000200082, doi:10.1212/nxg.0000000000200082. This article has 10 citations.
(khasminsky2023clinicoradiologiccriteriafor media 6adc2877): Vadim Khasminsky, Eitan Auriel, Judith Luckman, Ruth Eliahou, Edna Inbar, Keshet Pardo, Yuval Landau, Rani Barnea, Maor Mermelstein, Shahar Shelly, Jonathan Naftali, and Shlomi Peretz. Clinicoradiologic criteria for the diagnosis of stroke-like episodes in melas. Aug 2023. URL: https://doi.org/10.1212/nxg.0000000000200082, doi:10.1212/nxg.0000000000200082. This article has 10 citations.
(koga2018therapeuticregimenof pages 1-2): Yasutoshi Koga, Nataliya Povalko, Eisuke Inoue, Hidefumi Nakamura, Akiko Ishii, Yasuhiro Suzuki, Makoto Yoneda, Fumio Kanda, Masaya Kubota, Hisashi Okada, and Katsunori Fujii. Therapeutic regimen of l-arginine for melas: 9-year, prospective, multicenter, clinical research. Journal of Neurology, 265:2861-2874, Sep 2018. URL: https://doi.org/10.1007/s00415-018-9057-7, doi:10.1007/s00415-018-9057-7. This article has 108 citations and is from a domain leading peer-reviewed journal.
(argudo2022arginineforthe pages 4-5): Jennifer M Argudo, Olga M Astudillo Moncayo, Walter Insuasti, Gabriela Garofalo, Alex S Aguirre, Sebastian Encalada, Jose Villamarin, Sebastian Oña, Maria Gabriela Tenemaza, Ahmed Eissa-Garcés, Sakina Matcheswalla, and Juan Fernando Ortiz. Arginine for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes: a systematic review. Cureus, Dec 2022. URL: https://doi.org/10.7759/cureus.32709, doi:10.7759/cureus.32709. This article has 23 citations.
(na2024diagnosisandmanagement pages 12-14): Ji-Hoon Na and Young-Mock Lee. Diagnosis and management of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. Biomolecules, 14:1524, Nov 2024. URL: https://doi.org/10.3390/biom14121524, doi:10.3390/biom14121524. This article has 29 citations.
(NCT01339494 chunk 1): Fernando Scaglia. Nitric Oxide Production in MELAS Syndrome. Baylor College of Medicine. 2009. ClinicalTrials.gov Identifier: NCT01339494
(NCT03952234 chunk 1): Fernando Scaglia. L-Citrulline Dose Finding Safety Study in MELAS. Baylor College of Medicine. 2021. ClinicalTrials.gov Identifier: NCT03952234
(NCT06644534 chunk 1): A Study to Assess TTI-0102 vs Placebo in MELAS Patients. Thiogenesis Therapeutics, Inc.. 2025. ClinicalTrials.gov Identifier: NCT06644534

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Source YAML

References & Deep Research

References

Deep Research

MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes): Disease Characteristics Research Report

Executive summary

1. Disease information

1.1 What is the disease? (overview and definition)

1.2 Key identifiers

1.3 Synonyms and alternative names

1.4 Evidence provenance (individual patients vs disease resources)

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment / gene–gene interactions

3. Phenotypes

3.1 Core phenotype spectrum (with frequencies where available)

3.2 Phenotype characteristics (onset, severity, progression)

3.3 Quality-of-life impact

3.4 Suggested HPO terms

4. Genetic / molecular information

4.1 Causal genes

4.2 Pathogenic variants and heteroplasmy

4.3 Modifier genes / nuclear factors

4.4 Epigenetic and chromosomal abnormalities

5. Environmental information

6. Mechanism / pathophysiology

6.1 Molecular pathways and cellular processes

6.2 Metabolic changes and biochemical abnormalities

6.3 “Omics” and molecular profiling

6.4 Suggested ontology terms for mechanisms

7. Anatomical structures affected

7.1 Organ/system level

7.2 Tissue/cell and subcellular level

7.3 Neuroanatomical localization patterns (quantitative imaging)

8. Temporal development

8.1 Onset

8.2 Progression and course

9. Inheritance and population

9.1 Inheritance

9.2 Epidemiology (recent data prioritized)

9.3 Penetrance and expressivity (2024 large unselected cohort)

10. Diagnostics

10.1 Clinical and biochemical tests

10.2 Genetic testing

10.3 Clinicoradiologic criteria for stroke-like episodes (SLE) (real-world implementation)

11. Outcome / prognosis

11.1 Survival and mortality (cohort evidence)

11.2 Functional outcomes and prognostic markers (2024 cohort)

12. Treatment

12.1 Current standard of care (supportive)

12.2 Targeted symptomatic/preventive therapies for SLEs

Taurine (high-dose oral)

L-arginine (acute and prophylactic regimens)

Citrulline

12.3 Experimental / emerging therapies (pipeline)

13. Prevention

14. Other species / natural disease

15. Model organisms

Quantitative evidence summary table

Real-world implementations and clinical trials (selected)

Limitations of this evidence package (important for knowledge base curation)

Artifacts